-
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
Monday, December 12, 2022 - 1:25pm | 715Read More...Mental health care company COMPASS Pathways plc (NASDAQ: CMPS) has announced positive data demonstrating the potential of its proprietary synthetic psilocybin compound COMP360 in treating depression within Type II bipolar disorder. Presented at the American College of Neuropsychopharmacology...
-
Cannabis Has Unique Benefits For People With Bipolar Disorder, Says New Medical Research
Saturday, December 3, 2022 - 10:47am | 998Read More...This article was originally published on Cannabis.net and appears here with permission. Around 46 million people around the world struggle with the symptoms of bipolar disorder. Bipolar disorder can disrupt daily life, affecting relationships and ability to work. There are three...
-
FDA Pushes Review Of BioXcel's Candidate For Agitation Associated With Neuropsychiatric Disorders
Wednesday, December 1, 2021 - 12:08pm | 249Read More...The FDA has extended the review period for BioXcel Therapeutics Inc's (NASDAQ: BTAI) marketing application seeking approval for BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II. In connection with the FDA's...
-
Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med
Tuesday, June 1, 2021 - 9:35am | 153Read More...The FDA has approved Alkermes plc's (NASDAQ: ALKS) Lybalvi, a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity, for schizophrenia and bipolar I disorder. The approval comes as a maintenance...
-
BioXcel's Formulated Dexmedetomidine US Application For Agitation Under FDA Review
Wednesday, May 19, 2021 - 8:11am | 206Read More...The FDA has accepted for review, BioXcel Therapeutics Inc's (NASDAQ: BTAI) marketing application for BXCL501, an orally dissolving thin film formulation of dexmedetomidine. The application covers the acute treatment of agitation associated with schizophrenia and bipolar...
-
Intra-Cellular Therapies Files US Application For Expanded Use Of Lumateperone In Bipolar Settings
Monday, February 22, 2021 - 2:15pm | 159Read More...Intra-Cellular Therapies Inc (NASDAQ: ITCI) submits CAPLYTA (lumateperone) supplemental marketing application to the FDA to treat depressive episodes associated with bipolar I or II disorder in adults. The application seeks approval for two indications of CAPLYTA; as...
